LTR Pharma Limited (AU:LTP) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
LTR Pharma Limited’s Director, Lee Rodne, has been granted 100,000 unlisted options at an exercise price of $2.52, set to expire in December 2028. This change reflects shareholder approval during the company’s 2024 Annual General Meeting. Such updates may influence investor perceptions and market activity around LTR Pharma’s stock.
For further insights into AU:LTP stock, check out TipRanks’ Stock Analysis page.